Wyss Center Announces CE Mark for Its Brain Data Visualization Software, Epios Cloud
29.9.2021 12:00:00 EEST | Business Wire | Press release
The Wyss Center announced today the CE (Conformité Européenne) mark Class I medical device for its Epios Cloud software. Epios Cloud is a web-based application for the online storage, processing and review of neural signals, including the ultra-long-term data recorded by an emerging generation of devices for remote brain monitoring. Its novel features allow seamless navigation of datasets covering months and years while access through a web browser allows clinicians to access patient data anywhere and anytime.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210929005365/en/
Epios Cloud is a web-based application for online storage, processing and review of neural signals, including ultra-long-term data. (Photo: Wyss Center)
With the flexibility to connect to brain - or other bio-signal - recording devices over the web, Epios Cloud provides insights on multiple long-term data sources enabling clinicians to develop bespoke analytics to support personalized clinical decision making.
Clinicians are increasingly seeking options for outpatient neural monitoring over weeks to months. In epilepsy, home-based monitoring of brain activity during everyday life will help characterize the type and number of seizures, improve diagnosis and pre-surgical planning, and help build personalized treatment plans.
“We developed Epios Cloud as we needed software that would track not only when seizures occur but also the biosignals linked to epilepsy events. Epios Cloud allows us to synchronize neural data with heart rate or movement information over months or years. It gives us a glimpse of what is really going on in the brain during every-day life. In the future, additional data streams could easily be integrated into the platform to support other clinical applications. Importantly, centralized data storage will allow a fundamental change in automated analysis of neural data, allowing artificial intelligence algorithms to learn on an ever-growing global data lake – the development of which is already underway.” said Aleksander Sobolewski, PhD, Wyss Center Neuroscientist.
While current electroencephalogram (EEG) software is primarily optimized for the review of neural recordings that last minutes to hours, Epios Cloud is poised for the transition to longer-term recordings of weeks to months. Clinicians can also annotate the data with real-life events and develop novel analytics to automatically present regions of interest to complement visual screening.
George Kouvas, MBA, Wyss Center’s Chief Technology Officer said: “Epios Cloud is set to reveal new insights about epilepsy in individual patients – paving the way for personalized therapies. Now that Epios Cloud is CE marked, we look forward to connecting it to more brain recording modalities and to bringing this innovative long-term brain monitoring platform to more clinical or outpatient settings across Europe and beyond. Epios Cloud also has potential for use in stroke rehabilitation as well as neuromodulation of brain circuits for mental health applications.”
Epios Cloud is medical device software of Safety Class A as per IEC 62304 and CE-marked as Class I as per the Medical Device Directive 93/42/EEC. Epios Cloud is intended for displaying and reviewing electroencephalogram (EEG) recordings made by EEG devices using scalp and sub-scalp electrodes, heart rate and accelerometer measurements. The device is intended to be used by qualified medical practitioners. CE marking indicates that a product has been assessed and deemed to meet European Union safety, health and environmental protection requirements.
ENDS
About the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland
The Wyss Center is an independent, non-profit research and development organization that advances our understanding of the brain to realize therapies and improve lives.
The Wyss Center staff, together with the Center’s academic, clinical and industrial collaborators, pursue innovations and new approaches in neurobiology, neuroimaging and neurotechnology.
Wyss Center advances reveal unique insights into the mechanisms underlying the dynamics of the brain and the treatment of disease to accelerate the development of devices and therapies for unmet medical needs.
The Wyss Center was established by a generous donation from the Swiss entrepreneur and philanthropist Hansjörg Wyss in 2014. Additional resources from funding agencies and other sources help the Wyss Center accelerate its mission.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210929005365/en/
Contact information
MEDIA CONTACT:
Wyss Center
Jo Bowler, Communications Manager
+41 (0) 58 201 03 09
johanna.bowler@wysscenter.ch
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application12.11.2026 19:09:00 EET | Press release
VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes. Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by stati
WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network12.11.2026 19:00:00 EET | Press release
WHOOP, the human performance brand, today launched WHOOP Humans, a new feature that lets members follow friends and family, share fitness, health, and performance data they choose, and support each other's progress. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112176779/en/ WHOOP Launches WHOOP Humans, the Most Verifiably Human Social Network For more than a decade, WHOOP has helped members better understand their own health and performance. Now, WHOOP Humans extends that experience beyond the individual, making it easier to celebrate achievements, encourage progress, and look out for the people who matter most. "In a world that's becoming increasingly artificial, we're building something deeply human,” said Will Ahmed, Founder and CEO of WHOOP. “This is the most verifiably human network ever launched. Every account represents a real person with a verified heartbeat. They have real goals, challenges, and achievements. T
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 18:00:00 EET | Press release
The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and quantum chemistry to embed safety into chemical design from the outset. Adaptive catalytic systems: Led by the Max Planck Insti
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 17:00:00 EET | Press release
Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical applications. As India continues to play a critical role in supplying medicines to patients around the world, pharmaceutical manufacturers face increasing demands for quality, regulatory compliance,
Tigo Energy and Google Cloud Pair AI-Powered Tools for Solar Installers and Utilities12.11.2026 16:00:00 EET | Press release
Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a collaboration with Google Cloud to develop AI-enabled operational workflows for solar installers and distributed energy portfolios. By making core Tigo data and software products available through Google Cloud, Tigo aims to deliver faster deployment, simplified data integration, and additional insights with Gemini. The resulting workflows will help installers, asset managers, and energy operators more easily identify issues, prioritize actions, and automate routine operational tasks across growing fleets of distributed energy systems. As solar and storage portfolios expand, energy businesses are increasingly responsible for managing more sites, more system data, and more customer interactions without a proportional increase in operational resources. Through collaboration with Google Cloud, Tigo is developing AI-assisted workflows to help opera
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom